A pinboard by
this curator

Postdoctoral Fellow, Yale University


Transformina drug delivery polymer into a structural device for diabetic wound healing

My research is currently investigating novel biodegradable materials to accelerate wound healing in diabetic patients. The project involves the synthesis and characterization of a three component polymer known as Poly(amine-co-ester) (PACE). PACE has demonstrated superior biocompatibility and to better facilitate the delivery of genetic materials, especially siRNA, compared to other commercially available transfection agents. This polymer is unique in that is has a slight cationic charge and controllable hydrophobicity which is governed by the synthesis component parts and their ratios. The aims of the research include exploring various synthesis components and their ratios to optimize PACE for extended delivery of siRNA and the generation of a scaffold as a biodegradable wound dressing. PACE has not prior been transformed into a structural device but has been well investigate for gene and drug delivery applications. The efficacy and safety of these siRNA delivering scaffolds will be assessed both in in-vitro and in-vivo.


Diabetes in a Large Dementia Cohort: Clinical Characteristics and Treatment From the Swedish Dementia Registry.

Abstract: We aimed to investigate the differences in clinical characteristics and pharmacological treatment associated with the presence of diabetes in a large cohort of patients with dementia.A cross-sectional registry-based study was conducted using data from the Swedish Dementia Registry (SveDem). Data on dementia diagnosis, dementia type, and demographic determinants were extracted from SveDem. Data from Swedish Patient Register and Prescribed Drug Register were combined for the diagnosis of diabetes. Data on antidiabetic, dementia, cardiovascular, and psychotropic medication were extracted from the Swedish Prescribed Drug Register. Logistic regression was used to determine whether the variables were associated with diabetes after adjustment for confounders. In total, 29,630 patients were included in the study, and 4,881 (16.5%) of them received a diagnosis of diabetes.In the fully adjusted model, diabetes was associated with lower age at dementia diagnosis (odds ratio [OR] 0.97 [99% CI 0.97-0.98]), male sex (1.41 [1.27-1.55]), vascular dementia (1.17 [1.01-1.36]), and mixed dementia (1.21 [1.06-1.39]). Dementia with Lewy bodies (0.64 [0.44-0.94]), Parkinson's disease dementia (0.46 [0.28-0.75]), as well as treatment with antidepressants (0.85 [0.77-0.95]) were less common among patients with diabetes. Patients with diabetes who had Alzheimer's disease obtained significantly less treatment with cholinesterase inhibitors (0.78 [0.63-0.95]) and memantine (0.68 [0.54-0.85]).Patients with diabetes were younger at dementia diagnosis and obtained less dementia medication for Alzheimer's disease, suggesting less optimal dementia treatment. Future research should evaluate survival and differences in metabolic profile in patients with diabetes and different dementia disorders.

Pub.: 29 Jun '17, Pinned: 29 Jun '17